cGMP-compliant solutions company Akron Biotechnology revealed on Monday that it signed a supply agreement with Synairgen plc (LSE:SNG) for the latter's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate SNG001 for the treatment of COVID-19 patients.
Under Synairgen's Phase II trial of SNG001 in 101 hospitalized COVID-19 patients in July 2020, the inhaled IFN-beta could provide a valuable treatment option in the face of the global COVID-19 pandemic. The safety, biomarker and efficacy data for SNG001 provided from the interim analysis of its Phase II COPD trial in September 2020 was supportive of the on-going development in COVID-19 patients.
In conjunction with the agreement, Akron will support the future clinical and commercial development of SNG001 through the provision of its IFN-beta in Synairgen's formulation. The ability to rapidly scale the production of SNG001 will allow Synairgen to meet expected clinical and commercial demand for the drug, ensuring that patients have access to this promising treatment.
With focus primarily on lung viral defense in asthma, COPD and COVID-19, Synairgen uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review